

Deep vein thrombosis in a woman taking oral combined contraceptive pills

Kiran G. Piparva, Jatin G. Buch

Department of Pharmacology, P.D.U. Medical College, Rajkot, Gujarat, India.

ABSTRACT

Oral combined contraceptive pill (OCCP) is popular as birth control pills. Like all other drugs, they are not free from risks. Women taking certain types of OCCP have higher risk of developing deep vein thrombosis (DVT). A 29 year old married woman had taken OCCP for 3.5 months, developed deep vein thrombosis of left leg. Hereditary and acquired causes of DVT were excluded. She was treated with parenteral and oral anticoagulants simultaneously and was advised to discontinue OCCP. Initially the risk of blood clot was believed to be due to dose of estrogen but recent study relates it to the type of progesterone involved in OCCP. Thus, it is still a matter of debate, whether to associate risk of DVT to the amount of estrogen alone or also to the type of progestin. Apart from careful selection of patients, one should also look for the risk of venous thromboembolism irrespective of type of OCCP prescribed.

Key words: Deep vein thrombosis, hypercoagulability, oral combined contraceptive pill, thromboembolism

INTRODUCTION

Oral combined contraceptive pill (OCCP) is an effective form of birth control and is used to treat a number of other conditions. Like any other drug, OCCPs are not free from risks. Women taking OCCP have higher risk of developing deep vein thrombosis (DVT), usually in the legs, and this may lead to pulmonary embolism, a serious complication. For every 100,000 women aged 15–44 years not taking pill, approximately 5–10 are likely to develop blood clot in 1 year and this risk increases 3–4 times in those using second-generation OCCP and 6–8 times in those using third-generation OCCP.^[1]

CASE REPORT

A 29-year-old married woman was referred for surgical opinion for pain and swelling of left leg since 2 days. On examination, her left limb was swollen and tender. Color Doppler sonography confirmed early DVT. She also complained of nasal blockage and was diagnosed to have severe persistent asthma concomitantly. Except high erythrocyte sedimentation rate (ESR), complete blood count (CBC) and biochemical parameters were normal. She had history of taking OCCP (ethinylestradiol 30 µg, levonorgestrel 0.15 mg) since last 3.5 months for which she had consulted a gynecologist and also prednisolone on and off for allergic rhinitis. Wells Predictive pretest probability score was applied. Score for this patient was 1; thus, she had moderate pre-test probability for DVT (17% prevalence). She was treated with parenteral anticoagulant and simultaneously oral anticoagulant was started. She also received treatment for asthma (nebulized bronchodilators and inhaled steroid) concurrently. On discharge (5th day), she was advised to continue oral anticoagulant and local hirudoid cream for 2 weeks and continue medication for asthma. She was instructed for follow-up after 3 days for prothrombin

Access this article online	
Quick Response Code:	Website: www.jpharmacol.com
	DOI: 10.4103/0976-500X.83284

Address for correspondence:

Kiran G. Piparva, Department of Pharmacology, 12/15 Manhar Plot, "Panchjanya", Rajkot– 360 002, Gujarat, India.
E-mail: kiranpiparva@yahoo.co.in

time (PT)/International Normalized Ratio (INR) test. She was advised to discontinue OCCP.

DISCUSSION

The patient had no history of contributory factors that increase the risk of DVT (like immobility, overweight, pregnancy, smoking, major surgery).^[2,3] Special tests for DVT were negative which exclude hereditary and other acquired causes of hypercoagulability.^[4] Causality of DVT by OCCP was assessed by Naranjo's criteria and this adverse drug reaction was "probable" category.^[5]

In various generations of OCCP, estrogen is the common ingredient, while the type of progestogen is different. First generation OCCP contains lynestrenol. Second generation pills contain levonorgestrel or, less often, norgestrel, while third generation pills contain desogestrel or gestodene. Initially, estrogen was thought to increase the clot risk. Therefore, the dose of estrogen was lowered stepwise from 100 µg to 35–50 µg in newer generation pills.^[6] A recent Dutch study has shown that higher risk of developing blood clots is linked to new type of progestins such as drospirenone, desogestrel, lesser risk with gestodene, while levonorgestrel is still safer.^[6,7] Another study also supports the contention that risk of blood clots is higher with third generation pills.^[8] Thus, it is still a matter of debate whether to associate risk of DVT only to the amount of estrogen or also to the type of progestin. The patient reported here was using second generation OCCP, which is supposed to be safer than third generation pills. It is therefore suggested that apart from careful selection of patients, one should not overlook the

possibility of thromboembolic disorder irrespective of the type of OCCP prescribed.

REFERENCES

1. Medsafe patient information leaflets, oral contraceptives and blood clots. Available from: <http://www.medsafe.govt.nz/consumers/leaflets/oralcontraceptives.asp>. [Last accessed on 2010 Dec 3].
2. Schumacher F. Can Deep Vein Thrombosis Be Caused by Birth Control Pills? Available from: <http://health.ezinemark.com/can-deep-vein-thrombosis-be-caused-by-birth-control-pills-4f3c00dac6a.html> [Last accessed on 2010 Dec 3].
3. Goldhaber SZ. Deep vein thrombosis and pulmonary embolism. In: Fauci AS, Dennis L, Kasper LD, Dan L. Longo DL, Braunwald, *et al*, editors. Harrison's principle of internal medicine. 17th ed. New York: McGraw-Hill; 2008. p. 1651-7.
4. Hypercoagulable Disorders. Available from: http://www.labtestsonline.org/understanding/conditions/hypercoagulable_disorders.html [Last accessed on 2010 Dec 3].
5. Naranjo C, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, *et al*. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
6. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of estrogen dose and progestogen type: Results of the MEGA case-control study. BMJ 2009;339:b2921. Available from: <http://www.medscape.com/viewarticle/707597> [Last cited on 2009 Aug 21] [Last accessed on 2010 Dec 3].
7. Which Birth Control Pills Have the Lowest Blood Clots Risk? Available from: http://health.infoniac.com/which_birth_control_pills_have_lowest_blood_clots_sk.html [Last accessed on 2010 Dec 3].
8. Deep vein thrombosis and pills. Available from: <http://www.inate.org/en/1/2/6/19/default.aspx> (INATE- Investigators Against Thromboembolism- www.inate.org [Last accessed on 2010 Dec 3].

How to cite this article: Piparva KG, Buch JG. Deep vein thrombosis in a woman taking oral combined contraceptive pills. J Pharmacol Pharmacother 2011;2:185-6.

Source of Support: Nil, **Conflict of Interest:** None declared.

New features on the journal's website

Optimized content for mobile and hand-held devices

HTML pages have been optimized of mobile and other hand-held devices (such as iPad, Kindle, iPod) for faster browsing speed.

Click on **[Mobile Full text]** from Table of Contents page.

This is simple HTML version for faster download on mobiles (if viewed on desktop, it will be automatically redirected to full HTML version)

E-Pub for hand-held devices

EPUB is an open e-book standard recommended by The International Digital Publishing Forum which is designed for reflowable content i.e. the text display can be optimized for a particular display device.

Click on **[EPub]** from Table of Contents page.

There are various e-Pub readers such as for Windows: Digital Editions, OS X: Calibre/Bookworm, iPhone/iPod Touch/iPad: Stanza, and Linux: Calibre/Bookworm.

E-Book for desktop

One can also see the entire issue as printed here in a 'flip book' version on desktops.

Links are available from Current Issue as well as Archives pages.

Click on  View as eBook